Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:56 AM
Ignite Modification Date:
2025-12-25 @ 2:56 AM
NCT ID:
NCT00143533
Eligibility Criteria:
Inclusion Criteria:
* Subjects under 21 years of age at the time of initial diagnosis
* Recurrent solid tumors that have shown to be unresponsive to conventional treatment for their disease, or subjects with newly diagnosed tumors for whom no conventional treatment is available
* Histologic verification of solid tumor malignancy at original diagnosis
* Adequate performance status
* Neurologic deficits in subjects with central nervous system (CNS) tumors must have been relatively stable for a minimum of 2 weeks prior to study entry
* Subjects must have recovered from the toxic effects of all prior chemotherapy before entering the study
* Adequate bone marrow, renal and hepatic function
Exclusion Criteria:
* No active infection at time of protocol entry, and should not be receiving antibiotics other than P. carinii pneumonia prophylaxis.
* Patients must not be pregnant or lactating.
* Patients must not be taking an enzyme-inducing anticonvulsant (e.g., phenobarbital, phenytoin, or carbamazepine), rifampin, or St. John's Wort. Dexamethasone is not to be used as an antiemetic.
* Patients must not have had any previous allergic reactions to penicillin or cephalosporins.
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
20 Years
Study:
NCT00143533
Study Brief:
Protocol Section:
NCT00143533